NCT03173716

Brief Summary

This study is being done to find out if and how much the use of RTMPE improves a provider's confidence in the diagnosis they assign. This is important because the use of RTMPE may decrease the need for any additional invasive testing.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
24

participants targeted

Target at below P25 for phase_4

Timeline
Completed

Started Sep 2017

Typical duration for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 23, 2017

Completed
10 days until next milestone

First Posted

Study publicly available on registry

June 2, 2017

Completed
4 months until next milestone

Study Start

First participant enrolled

September 28, 2017

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2019

Completed
Last Updated

September 9, 2020

Status Verified

September 1, 2020

Enrollment Period

2.3 years

First QC Date

May 23, 2017

Last Update Submit

September 5, 2020

Conditions

Keywords

DEFINITY contrast

Outcome Measures

Primary Outcomes (1)

  • Change from Baseline Diagnostic Confidence Post-Echocardiography

    5-point Likert scale will be used to assess providers' diagnostic confidence

    through study completion, anticipated 1 year

Study Arms (2)

Intervention Group

ACTIVE COMPARATOR

DEFINITY contrast will be prepared according to package insert instructions. A dose of 1.5 mL activated DEFINITY diluted in 28.5 of preservative free saline to constitute a total volume of 30 mL will be infused at a rate of 90-120 mL/hr (1.5-2.0 mL/min). RTMPE will be performed.

Procedure: Definity

Control Arm

NO INTERVENTION

Echocardiograms will be performed without the use of DEFINITY contrast/RTMPE.

Interventions

DefinityPROCEDURE

Real-Time Myocardial Perfusion Echocardiography (RTMPE) will be performed as opposed to the standard echocardiogram (TTE) of the control arm

Intervention Group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adults age ≥ 18 years
  • Located in a designated ICU
  • TTE ordered by the primary care team
  • Significant delta in troponin trend
  • Concern for myocardial ischemia
  • Women of child-bearing potential must have a clinical negative pregnancy test result
  • Experienced sonographer available to complete RTMPE portion of the exam
  • Provider willing to complete the study survey

You may not qualify if:

  • Adults \< 18 years
  • Contraindication to echo contrast administration
  • Location other than an ICU
  • No significant delta in troponin trend

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mayo Clinic

Rochester, Minnesota, 55905, United States

Location

Related Links

MeSH Terms

Interventions

perflutren

Study Officials

  • Patricia A. Pellikka

    Mayo Clinic

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

May 23, 2017

First Posted

June 2, 2017

Study Start

September 28, 2017

Primary Completion

December 31, 2019

Study Completion

December 31, 2019

Last Updated

September 9, 2020

Record last verified: 2020-09

Locations